ATUM

1 / 1
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Leap-In Transposase

Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform

Wheeler Bio

PAO-06-24-CL-05May 30, 2024
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
CMC

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies

Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.

Wheeler Bio

PAO-07-23-CL-05Jul 26, 2023
Wheeler Bio
Cell Line Development Technology

Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering

Wheeler Bio

PR-M11-22-09Nov 30, 2022
Wheeler Bio
Series A Funding

Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma

Wheeler Bio

PR-M10-22-02Oct 05, 2022
1 / 1